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With primary central nervous system lymphoma (PCNSL) being a rare disease, the subtype of Burkitt lymphoma (BL) presenting as
a sole CNS lesion is an even more exceptional diagnosis. A case of coexistent primary CNS Burkitt lymphoma (PCNSBL) with
cerebral palsy (CP) is presented. A 55-year-old Caucasian male presented with increasing bilateral lower extremity weakness
above his baseline in addition to signs of increased intracranial pressure. Four abnormal enhancing masses were detected on
MRI with biopsy results consistent with Burkitt lymphoma. Complete staging workup was completed with no evidence of extraCNS disease noted on PET/CT, bone marrow biopsy, or cerebral spinal ﬂuid analysis. The patient was treated with intravenous
as well as intrathecal chemotherapy and found to be in a complete remission at six months. Recurrence in the CNS was
observed four months later with treatment consisting of whole brain radiation as well as intrathecal chemotherapy. Thirty
months after diagnosis, the patient remains disease-free. To our knowledge, this is the ﬁrst case of PCNSBL in the setting of CP.
A review of literature regarding treatment options in this controversial setting is provided.

1. Introduction
Primary central nervous system lymphoma (PCNSL) has
historically been an uncommon disease entity since it was
ﬁrst discovered. Recent reviews, however, indicate that cases
continue to arise at increasing numbers [1–3]. Incidence rose
three-fold between the years of 1973 and 1984; however, the
rate of increase is currently trending toward stabilization [4].
This is perhaps due to the invention of highly active antiretroviral therapy (HAART) for acquired immunodeﬁciency
syndrome (AIDS) as immunocompromised individuals
remain at 300% increased risk for PCNSL [3], and the
average age of diagnosis is 40 in the immunosuppressed
population versus 55–61 years of age in those who are immunocompetent [3]. Even as the incidence of PCNSL rises, it
remains a rare disease with a mere 7% incidence rate. The
subset of those individuals with primary CNS Burkitt lymphoma (PCNSBL) constitutes an even scarcer population
comprising just 3–5% of the PCNSL cases [1–3]. Only 36

cases of PCNSBL were found worldwide after a thorough
literature review (Table 1).
With such diminutive evidence on the most eﬀective way
to treat these patients, no standard of care exists, and the
chosen therapy has been anything but uniform. Many have
elected various combinations of intravenous (IV) chemotherapy, intrathecal (IT) chemotherapy, and radiation therapy. A backbone of IV high-dose methotrexate (HD-MTX)
proves to be the most signiﬁcant prognostic variable with
regard to treatment [3]. However, the optimal role for IT
MTX as well as radiation has yet to be deﬁned.
Recently, there has been doubt amongst professionals
whether whole brain radiation therapy (WBRT) should be
implored for these patients. In those who receive WBRT,
approximately 61% relapse within the radiation ﬁeld, and
the risk of signiﬁcant neurotoxicity, is 25–35% at 5 years with
death occurring in one-third of those patients [4–6]. This
toxicity proves especially detrimental in individuals greater
than 60 years of age [4], with recent assertions that using
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Table 1: Reported PCNSBL cases. Cy: cyclophosphamide; OS: overall survival; WBRT: whole brain radiation therapy; CHOP:
cyclophosphamide, doxorubicin, vincristine, and prednisone; Dex: dexamethasone; IVIG: intravenous immunoglobulin; MTX: methotrexate.
Author

Year Age/sex

How it is diagnosed (LP versus mass)

Tanaka et al. [20]
Tanaka et al. [20]

Left frontoparietal mass extending across
midline and through the skull
Left parietal, bilateral temporal, and post
1976 6 m/M
pituitary mass with abdominal and
periaortic nodal involvement
1977 49/M
Right thalamus to midbrain mass
1977 58/M
Right temporal mass

Tanaka et al. [20]

1977

42/M

Left deep parietal to occipital mass

Giromini et al. [11]
Hegedüs [21]

1981
1984

11/M
50/F

Left temporooccipital mass
Right lower parietal lobe mass

Kobayashi [22]

1984

55/F

Right temporoparietal mass

Pui et al. [23]

1985

6/M

T2-5 mass

Pui et al. [23]

1985

7/M

C7-T4 mass

Pui et al. [23]

1985

12/M

T7-10 mass

Mizugami et al. [24]

1987

6/M

T10 mass

Mizugami et al. [24]

1987

5/M

Epidural T12-L4 mass

Mizugami et al. [24]

1987

7/F

T11 mass

Shigemori et al. [25]

1991

49/F

Left frontal lobe mass

Tekkök et al. [12]

1991

5/M

Parasellar mass, extending to bilateral
sphenoids and sella turcica

Toren et al. [26]

1994

6/F

CSF

Mora and Wollner [7]

1999

18/M

T11 mass

Mora and Wollner [7]

1999

9/M

Epidural T9-11 mass

Spath-Schwalbe et al. [27] 1999

40/M

Cerebellum and pons masses

Wilkening et al. [28]

2001

43/F

L2-3 epidural tumor involving the
dura and cauda equina

Monabati et al. [29]

2002

49/F

Right parietal mass

Daley et al. [30]

2003

13/F

L1-2 epidural mass

Gawish [18]
Valsamis et al. [19]

1976

8/M

Treatment and OS
Complete resection with recurrence. Subtotal
resection with Cy. OS of 3 years
Resection, steroids, WBRT, and spinal irradiation
with recurrence, IT MTX. OS of 23 months
Subtotal resection. OS of 4.5 years
Subtotal resection. Recurrence. OS 3 months
Pred with partial resection. Recurrence.
Vincristine and Cy with radiation. Vincristine,
bleomycin, Cy, steroids. OS of 2.5 years
Complete resection
Post mortem ﬁnding
Complete resection. Recurrence with reresection.
OS of 2 months
Laminectomy and CHOP (without prednisone).
OS > 2 years
Laminectomy, radiation, dex, and Cy.
Recurrence. OS of 5 months
Laminectomy, CHOP (substituting dex for
prednisone). OS of 4 months
Near complete resection, radiation, and
chemotherapy. Leukemic transformation then CSF
recurrence. IT MTX and cranial irradiation.
OS of 20 months
Near complete resection, radiation, and
chemotherapy with recurrence. OS of 7 months
Near complete resection. Spinal radiation and
chemotherapy with progression of disease.
OS of 3 months
Resection, radiation, CHOP, and IT MTX.
OS of >6 months
Partial resection, craniospinal radiation, CHOP, and
IT MTX/cytarabine/prednisone. OS > 18 months
Steroids, IVIG, doxorubicin, vincristine, HD MTX,
with IT MTX, cytarabine, and hydrocortisone.
Changed to CHOP with MTX and IT MTX,
cytarabine, hydrocortisone. OS of >2 years
Laminectomy with CHOP substitute daunorubicin
for doxorubicin and radiation. Relapse and refused
further treatment. OS > 8 months
Laminectomy, dex, radiation, and CHOP
(substituting daunorubicin for doxorubicin).
Recurrence and given chemotherapy via LSA3
protocol. Second recurrence, received
palliative radiation. OS > 1 year
MTX and WBRT. OS > 1 year
Complete resection, radiation, IT MTX, and
MTX with ifosfamide and CHOP (with dex
substituted for prednisone). OS of >2 years
Complete resection, CHOP, and craniospinal
radiation. Refused further treatment.
OS of >6 months
Complete excision, CHOP with MTX, and IT
MTX and cytarabine and steroids. OS of >5 years
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Table 1: Continued.

Author

Year Age/sex

How it is diagnosed (LP versus mass)

Shehu [31]

2003

8/M

Left temporal and right orbit masses

Abel et al. [32]

2006

50/M

Gobbato et al. [15]

2006

38/M

Kozáková et al. [33]
Gu et al. [34]
Takasu et al. [35]

2008
2010
2010

60/F
75/F
71/M

Central and right thalamus mass
Right frontotemporoparietal
subdural mass
Sellar/pituitary mass
Third and left lateral ventricle masses
Hypothalamus and third ventricle mass

Jiang et al. [36]

2011

14/M

Right lateral ventricle mass

Lim et al. [10]

2011

43/F

Akhaddar et al. [37]

2012

13/F

Jiang et al. [38]

2012

69/M

Yoon et al. [39]

2012

10/M

Yoon et al. [39]

2012 32 m/M

Alabdulsalam et al. [40]

2014

18/M

Medulla oblongata mass,
CSF involvement
Right infratemporal and cavernous/
maxillary/sphenoethmoidal sinus mass
Right temporal and occipital lobe,
cervical spine, and cauda equina masses;
CSF involvement
Suprasellar, cerebellum, and 3rd
ventricle masses; CSF involvement

Sellar mass extending to
orbit/sphenoid, CSF involvement

4th ventricle mass

WBRT in children is no longer necessary or acceptable due to
signiﬁcant risk of long-term neurotoxicity [7]. The German
PCNSL Study Group is the largest and only phase III randomized trial comparing IV chemotherapy ± WBRT which
revealed no signiﬁcant diﬀerence in overall survival (OS)
(44.2 versus 59.0 months, p = 0 78) when WBRT was added
to HD-MTX-based chemotherapy in those patients with a
complete response (CR) [8]. In a subset of patients who did
not reach a CR, however, the addition of WBRT did show
prolonged progression-free survival (PFS) (5.0 versus 2.9
months, p = 0 002) but did reveal a diﬀerence in OS (27.4
versus 18.2 months, p = 0 119) [8].
Several diﬀerent therapeutic options, including IT chemotherapy and complete surgical resection, have also been
questioned. As IV HD-MTX crosses the blood-brain barrier, many believe IT only increases toxicity with little to
no additional beneﬁt. Complete resection of the tumor
has also been challenged in the past as it potentially
increases neurologic deﬁcits without any survival beneﬁt
[5]. Recently, the German PCNSL Study Group-1
(GPSG-1) trial has refuted this, stating there may be signiﬁcant PFS [2]. Discrepancies may be attributed to the advances
that have been made in neurosurgical techniques over the last
decade [2].

Treatment and OS
Cy, vincristine, and MTX with IT cytosine
arabinoside. OS of 11 months
Unknown
Craniotomy. OS of 11 days
Complete resection
WBRT. OS of >9 months
Partial resection and WBRT
Complete resection, radiation, and MTX,
vincristine, predisone, and leucovorin.
OS of >18 months
MTX, vincristine, and procarbazine with
IT MTX and WBRT. OS of 7 months
Chemotherapy
DLBCL/BL subtype. WBRT, spinal
radiation with recurrence. HD MTX and
cytarabine with rituximab
HD MTX and cytarabine with IT cytarabine,
MTX, and hydrocortisone. OS of >7 years
HD MTX and cytarabine with IT cytarabine,
MTX, and hydrocortisone. Relapse, treated with
IT cytarabine, MTX, and hydrocortisone with
WBRT and spinal radiation. Then received
prednisone, vincristine, and cyclophosphamide
with IT. OS of 9 months
Craniotomy with HD MTX with
rituximab-CHOP and IT MTX, cytarabine, and
hydrocortisone. OS of >18 months

Patients with PCNSL have an extremely poor prognosis,
with an OS of approximately 12–18 months [1, 3, 9]. Without
treatment, this number dwindles to 1.5–3.3 months [10].
Therefore, it is imperative that this disease be treated with
the best available option to improve the expected survival
of these individuals. Here, we present a case of an adult
HIV-negative male with PCNSBL in the setting of cerebral
palsy (CP) and our approach to treatment with long-term
follow-up.

2. Case
A 55-year-old Caucasian male with past medical history of
cerebral palsy (CP) presented with nausea, vomiting, thirtypound weight loss, and worsening bilateral lower extremity
weakness for one month. A computerized tomography
(CT) angiogram of the brain revealed a suprasellar mass
facilitating transfer to our institution for further management. Magnetic resonance imaging (MRI) of the brain indicated abnormal enhancement along the ependymal margin
of the frontal horns of the bilateral lateral ventricles with four
distinct abnormal enhancing mass lesions in the hypothalamus (11 × 12 × 13 mm), pineal gland (8 × 8 × 9 mm), the trigon of the right lateral ventricle (5 × 5 × 4 mm), and the
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Figure 1: MRI brain, T1 sagittal + gadolinium, demonstrated lesions
within hypothalamus, pineal gland, trigon of the right lateral
ventricle, and foramen of Magendie at diagnosis.

Figure 2: MRI brain, T1 sagittal + gadolinium, revealing complete
resolution of all four mass lesions after receiving IV and IT
chemotherapy.

foramen of Magendie (7 × 6 × 9 mm) which demonstrated
restriction diﬀusion indicating hypercellularity (Figure 1).
An endoscopic biopsy of the third ventricle ﬂoor lesion
was performed with pathology revealing sheets of intermediate size monotonous lymphoid cells displaying high nuclearto-cytoplasmic ratio with dispersed chromatin and indistinct
nucleoli. Numerous apoptotic cells and mitotic ﬁgures with
foci of necrosis were observed. The tumor cells displayed
CD 20 with coexpression of CD 10 and were negative for
BCL 2, BCL 6, CD 3, and CD 5. EBER in situ hybridization
was also negative. Fluorescent in situ hybridization was positive for [11, 12] (MYC/IHG) fusion in 97% of the cells and
loss of BCL2 in 96%. These results appeared to be consistent
with Burkitt lymphoma.
Staging workup was obtained which only revealed concern for extra cranial disease present at T12-L1 and L2-L3
consistent with subarachnoid nodular pial metastases on
MRI of the lumbosacral spine. PET/CT disclosed no evidence
of extra-CNS disease. A lumbar puncture and bone marrow
biopsy were performed and found to be negative for disease.
In the absence of extra-CNS disease, the patient was diagnosed with PCNSBL.
Patient was started on IV HD-MTX (3.5 grams per
meter squared) and cytarabine (2 grams per meter
squared) per Ferreri regimen [13] with the addition of
IT MTX/cytarabine every 21 days for four cycles. Dose
was reduced by 25% for cycle three due to persistent cytopenias and toxicity including renal dysfunction with delayed
MTX clearance. A repeat brain MRI was obtained after 6
months which indicated complete remission with no
evidence of disease (Figure 2).
Four months later, the patient began having generalized
weakness with visual disturbances and headaches. A repeat
brain MRI at that time revealed interval development of
markedly abnormal signal in the pons extending to the midbrain and dorsal medulla. Repeat cerebral spinal ﬂuid (CSF)
analysis showed rare atypical lymphocytes consistent with
relapse of lymphoma. He underwent WBRT, receiving 30
Gray (Gy) over 17 fractions with an additional boost to the
midbrain lesion with 9 Gy in 8 fractions. Currently, he is
disease-free at 30 months s/p diagnosis.

3. Discussion
To our knowledge, our patient is the only PCNSBL case with
a past medical history of CP. No literature was discovered
that revealed a connection between these two diseases, and
further research may be warranted if similar cases develop
in the future. It would have been easy to dismiss the presenting symptoms as part of his CP; therefore, caution must be
taken to not be blinded by a patient’s past medical history
in attempting to decipher the etiology of new symptoms. Primary CNS lymphoma should remain a consideration for
those presenting with neurological symptoms regardless of
their history.
The optimal treatment for PCNSBL continues to elude
us, and no standard of care exists at this time. The paucity
of cases provides little opportunity for randomized controlled trials; therefore, clinicians have been forced to extrapolate based upon recommendations for Burkitt lymphoma
residing outside as well as PCNSL regimens. Many of the
reported cases of PCNSBL used HD-MTX +/−, some variation of cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) therapy. A few studies attempted additional agents such as ifosfamide and procarbazine, but had
little success. Several used IT MTX alone or in combination
with cytarabine and steroids.
Our treatment decision was based upon the Ferreri regimen, which is the only randomized trial for PCNSL [13].
Since our patient suﬀered from the added rarity of Burkitt
lymphoma subtype, the addition of IT chemotherapy was
made based on standard practice for extra-CNS Burkitt lymphoma as it has a high incidence of CNS penetration. While
there has been some debate regarding the need for IT chemotherapy in addition to IV HD-MTX, these patients were
mostly non-Burkitt type (diﬀuse large B cell) PCNSL. Even
with the baseline cognitive deﬁcits of our patient, he was able
to tolerate an aggressive chemotherapy regimen that
included IT and eventually WBRT without any permanent
neurological complications to date. Although he did develop
some mild delirium while hospitalized for WBRT and IT
MTX after relapse, this promptly resolved prior to discharge.
The decision at that time was made to withhold any further
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IT therapy as no further evidence of disease was present and
the risk of toxicities outweighed the current beneﬁts. He
remains disease-free at 30 months.
The role of IT therapy has been challenged in the face of
HD-MTX therapy being able to cross the BBB. Ferreri et al.
have shown that there is no survival beneﬁt when using IT
in addition to HD-MTX with regard to PCNSL of all types,
with 2-year OS rates of 51 ± 5% with IT versus 50 ± 6% without IT [14]. There are also reports of increased neurotoxicity
when adding concurrent IT to HD-MTX with no survival
beneﬁt [8]. Neither of these studies separated those with Burkitt subtype, however. Therefore, our decision for IT administration was based upon extrapolation from accepted
therapy for extra-CNS Burkitt lymphoma being IT MTX/
Ara-C in addition to systemic chemotherapy.
We present a case of relapsed lymphoma that responded
to WBRT of 30 Gray in 17 fractions with boost of 9 Gray in 8
fractions which was tolerated well with a complete response
(CR), and no evidence of disease at 18 months after radiation
was completed. Many studies have attempted to investigate
the beneﬁts and toxicities associated with the use of WBRT,
which challenges the prior approach to this entity. There
seems to be a trend away from WBRT, especially in those
individuals > 60 years of age and children with no evidence
of residual disease after IV chemotherapy, as long-term neurocognitive consequences have been found to outweigh the
beneﬁt gained by these patients with neurotoxicity being fatal
even without evidence of recurrent disease [4].
Recent studies have shown no OS beneﬁt when adding
upfront WBRT to HD-MTX-containing regimens. Ferreri
et al. have shown an OS of 25 ± 4% at 2 years with WBRT
alone which was signiﬁcantly inferior to both MTXcontaining chemotherapy as well as MTX combined with
WBRT, revealing a 2-year OS of 34 ± 10% and 45 ± 3%,
respectively [14]. This OS diﬀerence between WBRT with
MTX versus MTX alone was not signiﬁcant; therefore, it is
suggested that those individuals at a high risk of neurotoxicity forego WBRT unless relapse or refractory disease is
apparent. We therefore chose to forego WBRT in the initial
setting, reserving it for relapsed disease in our patient. Debate
also exists regarding the optimal dose of WBRT, as each
study utilized diﬀerent fractions and dosages. Hyperfractionation has also been noted to have increase toxicity as compared to standard dosage with neurotoxicity rates of 23%
and 3.7%, respectively [5]. This has been shown to be most
prevalent in those receiving > 50 Gray [9].
The concept of complete surgical resection has fallen
under scrutiny in recent years as well. Previously, many subscribed to complete resection of the mass with recent reports
challenging this citing an increase in postoperative neurological deﬁcits with no OS beneﬁt [2, 3, 15]. Currently, the
decision for excision when CNS lesions are the only areas
of disease is made on a case by case basis with regard to
tumor location and expected postsurgical deﬁcits.
Despite adequate initial treatment with chemotherapy
with or without WBRT, approximately 40–50% of PCNSL
patients relapse within the ﬁrst 5 years [3]. This obviates
the need for obtaining better treatment modalities, not only
ﬁrst line but also for relapsed or refractory disease. The
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median post relapse survival rate approximates 2 months
with a 2-year OS of 8% [3]. Our patient is now 18 months
status post a second CR. A few small studies have evaluated
the role of bone marrow transplant as a potential treatment for PCNSL in the relapsed and refractory setting as
these individuals have a signiﬁcantly increased risk of death
[2, 16, 17]. Randomized phase II trials must be undertaken
to thoroughly evaluate this option with regard to such a
speciﬁc disease population.
Our patient subscribed to the current statistics of recurrence of disease within the ﬁrst ﬁve years despite a complete
response to initial treatment. He is currently disease-free for
18 months after reinduction with WBRT, which is longer
than the average survival of such individuals, and remains
without any signiﬁcant neurotoxicity. Using our approach
of IV and IT chemotherapy in PCNSBL upfront and reserving WBRT for the relapsed setting, our patient has far
exceeded the median post relapse survival rate. This suggests
a potential beneﬁt to our approach. Regardless of the relatively favorable outcome of our patient, it remains that clear
optimal treatment continues to be elusive. Substantial
advances are required with regard to PCNSBL, as it remains
a signiﬁcant challenge to patients and physicians alike.
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